UK Zocor Experience Inadequate To Sway FDA Panel On Mevacor
This article was originally published in The Tan Sheet
J&J/Merck could have benefited from a minimum of one-year UK consumer-use data of 10 mg simvastatin before facing a panel with its lovastatin 20 mg switch proposal in the U.S
You may also be interested in...
A joint FDA panel decision to recommend against approval of over-the-counter Mevacor Daily was tempered by the endorsement of a behind-the-counter drug class by a number of panelists
Customers who present at UK pharmacies to purchase McNeil Europe's Zocor Heart-Pro (simvastatin 10 mg) without a prescription will need to disclose risk factors such as age and family history of heart disease, but not necessarily their cholesterol level, under a marketing plan cleared by the UK health agency
Perrigo promotes in pricing, planning